Project Grant HT94252310644
Award Date 9/30/23
Completion Date 9/29/26
Dollars Obligated $2.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration has been awarded $240,897 under the Military Medical Research and Development program (CFDA 12.420), administered by the Defense Health Agency. The award, effective August 1, 2025, through July 31, 2027, supports integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma (SEGA) at single-cell resolution. This research initiative investigates cellular and molecular characteristics of...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.0M Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The project focuses on developing a novel umbilical cord blood-derived cell therapy designed to suppress neuroinflammation and promote remyelination. This research initiative addresses critical neurological conditions...
- This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
- This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,493,233 to The Trustees of Columbia University in the City of New York to fund research on gene therapy in a nonhuman primate model of cognitive defects in Parkinson's disease. The award commenced on November 15, 2024 and is set to be completed by November 14, 2027. The university's Health Sciences Division will leverage its...
- This $661,501 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the period of September 1, 2024 through August 31, 2027. The award will fund research to develop AAV (adeno-associated virus) vectors targeted to muscle and muscle stem cells, which offer improved therapeutic efficacy and safety for treating Duchenne muscular dystrophy. UCLA, through...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
- Federal Grant Award Summary Duke University's Office of Research Administration has been awarded $700,032 through the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, through July 31, 2029. The project, titled "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in RCC," represents a four-year research initiative conducted at Duke University in Durham, North Carolina. This...
- This federal Project Grant award in the amount of $6,407,037.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports "IND-ENABLING STUDIES FOR AN RNA THERAPEUTIC TO TREAT ATHEROSCLEROSIS" at Duke University, with a performance period from November 1, 2024 to October 31, 2028. The funding will enable Duke University's Office of Research Administration to conduct critical research and development work...
- Federal Project Grant Award Summary Duke University received a $3.19 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 21, 2025, with a completion date of July 31, 2029. The research focuses on addressing critical immunological challenges associated with recombinant adeno-associated virus (AAV) gene therapy delivery. AAV vectors have emerged as promising...
- This $1,995,027 Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research on therapy for C9ALS (chromosome 9-linked amyotrophic lateral sclerosis) using engineered RNA-targeting zinc finger proteins. The award was made to UC San Diego effective June 1, 2025, with performance concluding on May 31, 2028. The research aims to develop and validate novel therapeutic approaches targeting the genetic basis of...